Cytochrome P-450 Enzyme Inhibitors
"Cytochrome P-450 Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 ENZYMES.
| Descriptor ID |
D065607
|
| MeSH Number(s) |
D27.505.389.500 D27.505.519.389.335
|
| Concept/Terms |
Cytochrome P-450 Enzyme Inhibitors- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P 450 Enzyme Inhibitors
- P-450 Enzyme Inhibitors
- Enzyme Inhibitors, P-450
- Inhibitors, P-450 Enzyme
- P 450 Enzyme Inhibitors
- P450 Enzyme Inhibitors
- Enzyme Inhibitors, P450
- Inhibitors, P450 Enzyme
- Cytochrome P-450 Inhibitors
- Cytochrome P 450 Inhibitors
- Inhibitors, Cytochrome P-450
- P-450 Inhibitors, Cytochrome
Cytochrome P-450 Monooxygenase Inhibitors- Cytochrome P-450 Monooxygenase Inhibitors
- Cytochrome P 450 Monooxygenase Inhibitors
- Cytochrome P-450-Dependent Monooxygenase Inhibitors
- Cytochrome P 450 Dependent Monooxygenase Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 Enzyme Inhibitors".
This graph shows the total number of publications written about "Cytochrome P-450 Enzyme Inhibitors" by people in this website by year, and whether "Cytochrome P-450 Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytochrome P-450 Enzyme Inhibitors" by people in Profiles.
-
Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. Am J Health Syst Pharm. 2015 Jun 01; 72(11):958-65.
-
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015 Mar; 16(3):338-48.
-
CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids. 2015 Mar; 95:80-7.
-
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov; 66(5):815-25.
-
Design and synthesis of potent, orally efficacious hydroxyethylamine derived ?-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors. J Med Chem. 2012 Nov 08; 55(21):9025-44.
-
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst. 2011 Feb 02; 103(3):264-72.
-
Potent inhibition of human cytochrome P450 1B1 by tetramethoxystilbene. Toxicol Lett. 2009 Aug 25; 189(1):84-9.
-
The atherogen 3-methylcholanthrene induces multiple DNA adducts in mouse aortic smooth muscle cells: role of cytochrome P4501B1. Cardiovasc Res. 2002 Mar; 53(4):1002-9.
-
Potentiation of oxygen-induced lung injury in rats by the mechanism-based cytochrome P-450 inhibitor, 1-aminobenzotriazole. J Pharmacol Exp Ther. 2000 Feb; 292(2):553-60.
-
Protein-reactive metabolites of carbamazepine in mouse liver microsomes. Drug Metab Dispos. 1996 May; 24(5):509-14.